Clinicopathological and Prognostic Significance of Epidermal Growth Factor-Like Domain 7 (EGFL7) Overexpression in Primary Central Nervous System Tumor: A Meta-Analysis
https://doi.org/10.35401/2541-9897-2025-10-3-37-44
Abstract
Background: Central nervous system (CNS) tumors are associated with high rates of progression and mortality. Several biomarkers have been identified and investigated for their role in tumor progression, including Epidermal Growth Factor-Like Domain 7 (EGFL7). This study aims to evaluate the clinicopathological and prognostic significance of EGFL7 overexpression in CNS tumor.
Methods: The literature search was conducted using PubMed, ScienceDirect, and Web of Science. Studies were selected according to PRISMA guidelines and analyzed using Review Manager 5.4 (Cochrane Collaboration, UK).
Results: A total of 313 patients with CNS tumors from six eligible studies were included in this meta-analysis. EGFL7 overexpression was significantly associated with tumor grade and Karnofsky Performance Status (KPS) score (OR, 6.86; 95% CI, 2.41 – 19.57; p, 0.0003; and OR, 2.92; 95% CI, 1.52 – 5.59; p, 0.001 respectively). Furthermore, EGFL7 overexpression was significantly associated with the poorer overall survival (HR, 1.64; 95% CI, 1.02 – 2.63; p, 0.04).
Conclusions: EGFL7 overexpression is associated with clinicopathologic characteristics and patient prognosis in CNS tumors. This highlights the potential of the marker as a valuable tool for diagnosis and disease risk assessment, contributing to enhanced personalization of treatment strategies and cancer monitoring.
About the Authors
IGAP Sasmana
Udayana University
Indonesia
Indonesia
I Gede Aswin Parisya Sasmana, MBBS, Junior Oncology Research Scientist, Faculty of Medicine
Bali 80232
S. Wiranata
Udayana University
Indonesia
Indonesia
Sinta Wiranata, MD, Junior Neurosurgery Research Scientist, Faculty of Medicine
Bali 80232
IGNAW Kusuma
Udayana University
Indonesia
Indonesia
Gusti Ngurah Ananda Wira Kusuma, MD, Junior Oncology Research Scientist, Faculty of Medicine
Bali 80232
IGP Supadmanaba
Udayana University
Indonesia
Indonesia
Gede Putu Supadmanaba, MD, M.Sc, Senior Oncology Research Scientist, Department of Biochemistry, Faculty of Medicine
Bali 80232
D. M. Wihandani
Udayana University
Indonesia
Indonesia
Desak Made Wihandani, MD, MHealSc, PhD, Professor, Senior Research Scientist of Medicine, Metabolic Syndrome, and Oncology, Department of Biochemistry, Faculty of Medicine
Bali 80232
References
1. Perkins A, Liu G. Primary Brain Tumors in Adults: Diagnosis and Treatment. Am Fam Physician. 2016;93(3):211-217. PMID: 26926614.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. PMID: 30207593. https:// doi.org/10.3322/caac.21492
3. Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of Brain Tumors. Neurol Clin. 2018;36(3):395-419. PMID: 30072062. https://doi.org/10.1016/j.ncl.2018.04.001
4. Tavassoly O, Sato T, Tavassoly I. Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries. Mol Pharmacol. 2020;98(1):13-22. PMID: 32350120. https://doi.org/10.1124/mol.120.119909
5. Suina K, Tsuchihashi K, Yamasaki J, et al. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. Cancer Sci. 2018;109(12):3874-3882. PMID: 30298963. PMCID: PMC6272110. https://doi.org/10.1111/cas.13826
6. Das P, Puri T, Jha P, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci. 2011;18(1):66-70. PMID: 20888234. https://doi.org/10.1016/j.jocn.2010.04.050
7. Yang P, Liang T, Zhang C, et al. Clinicopathological factors predictive of postoperative seizures in patients with gliomas. Seizure. 2016;35:93-99. PMID: 26808114. https://doi.org/10.1016/j.seizure.2015.12.013
8. Benito R, Gil-Benso R, Quilis V, et al. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Neuropathology. 2010;30(4):392-400. PMID: 20051017. https://doi.org/10.1111/j.1440-1789.2009.01081.x
9. Yamauchi M, Fukuda T, Wada T, et al. Expression of epidermal growth factor-like domain 7 may be a predictive marker of the effect of neoadjuvant chemotherapy for locally advanced uterine cervical cancer. Oncol Lett. 2016;12(6):5183-5189. PMID: 28105226. PMCID: PMC5228482. https://doi.org/10.3892/ol.2016.5318
10. Luo W, Shao C, Li N, et al. Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma. Am J Transl Res. 2015;7(7):1236-1245. PMID: 26328008. PMCID: PMC4548316.
11. Zhou L, Li J, Zhao YP, et al. Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2014;13(5):523-528. PMID: 25308363. https://doi.org/10.1016/s1499-3872(14)60272-1
12. Hansen TF, Christensen Rd, Andersen RF, Sørensen FB, Johnsson A, Jakobsen A. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer. 2013;109(5):1243-1251. PMID: 23922111. PMCID: PMC3778299. https://doi.org/10.1038/bjc.2013.448
13. Oh J, Park SH, Lee TS, Oh HK, Choi JH, Choi YS. High expression of epidermal growth factor-like domain 7 is correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer. J Gynecol Oncol. 2014;25(4):334-341. PMID: 25142627. PMCID: PMC4195305. https://doi.org/10.3802/jgo.2014.25.4.334
14. Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology. 2009;50(6):1839-1850. PMID: 19824075. https://doi.org/10.1002/hep.23197
15. Sasmana I, Putri P, Dewi N, Supadmanaba I, Wihandani D. Current Development of Virotherapy in Breast Cancer: A Brief Review. Acta Medica Bulg. 2024;51(4):86-94. https://doi.org/10.2478/AMB-2024-0084
16. Sasmana IGAP, Wiranata S, Yogananda KC, Wihandani DM, Supadmanaba IGP. Clinicopathological and Prognostic Significance of SRY-Box Transcription Factor 2 (SOX2) Overexpression in Central Nervous System Tumor: A Meta-Analysis. Bali Med J. 2023;12(2):1733-1739. https://doi.org/10.15562/bmj.v12i2.4493
17. Huang CH, Li XJ, Zhou YZ, Luo Y, Li C, Yuan XR. Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol. 2010;136(11):1737-1743. PMID: 20213100. PMCID: PMC11828204. https://doi.org/10.1007/s00432-010-0832-9
18. Nichol D, Stuhlmann H. EGFL7: a unique angiogenic signaling factor in vascular development and disease. Blood. 2012;119(6):1345-1352. PMID: 22160377. PMCID: PMC3286203. https://doi.org/10.1182/blood-2011-10-322446
19. da Costa BHB, Becker AP, Neder L, et al. EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome. J Pathol Transl Med. 2022;56(4):205-211. PMID: 35698739. PMCID: PMC9288890. https://doi.org/10.4132/jptm.2022.04.22
20. Wang J, Liu Q, Gao H, et al. EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway. Tumour Biol. 2017;39(7):1010428317706203. PMID: 28705113. https://doi.org/10.1177/1010428317706203
21. Brunhara BB, Becker AP, Neder L, et al. Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas. Neuropathology. 2021;41(1):21-28. PMID: 33191640. https://doi.org/10.1111/neup.12698
22. Liu M, Yang P, Mao G, et al. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: A systematic review and meta-analysis. Int J Surg. 2019;72:206-213. PMID: 31734255. https://doi.org/10.1016/j.ijsu.2019.11.004
23. Wang XX, Yao XB, Qiang ZS, Zhu HL. Attenuation of EGFL7 inhibits human laryngocarcinoma cells growth and invasion. Int J Clin Exp Med. 2015;8(3):3141-3155. PMID: 26064204. PMCID: PMC4443038
24. Luo BH, Xiong F, Wang JP, et al. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PLoS One. 2014;9(6):e99922. PMID: 24945379. PMCID: PMC4063792. https://doi.org/10.1371/journal.pone.0099922
25. Massimiani M, Vecchione L, Piccirilli D, et al. Epidermal growth factor-like domain 7 promotes migration and invasion of human trophoblast cells through activation of MAPK, PI3K and NOTCH signaling pathways. Mol Hum Reprod. 2015;21(5):435-451. PMID: 25667199. PMCID: PMC4492406. https://doi.org/10.1093/molehr/gav006
26. Sriwidyani NP, Wahyuniari IAI, Saputra H, Arijana IGKN. Idh1 mutation in balinese glioma patients and its relationship with clinicopathological parameters. Bali Med J. 2020;9(3):819-822. https://doi.org/10.15562/bmj.v9i3.2077
27. Sabunga OD, Kaelan C, Miskad UA, Zainuddin AA, Sungowati NK, Cangara MH. Analysis of Isocitrate Dehydrogenase (IDH) expression in astrocytoma patients: cases of South Sulawesi, Indonesia. Bali Med J. 2022;11(1):184-188. https://doi.org/10.15562/bmj.v11i1.3078
28. Ichwan S, Ningsih HL, Aman RA, et al. O6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status of high-grade and low-grade gliomas. Bali Med J. 2021;10(2):644-647. https://doi.org/10.15562/bmj.v10i2.2316
29. Huang CH, Li XJ, Zhou YZ, Luo Y, Li C, Yuan XR. Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol. 2010;136(11):1737-1743. PMID: 20213100. PMCID: PMC11828204. https://doi.org/10.1007/s00432-010-0832-9
30. Huang CH, Li XJ, Zhou YZ, Luo Y, Li C, Yuan XR. Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol. 2010;136(11):1737-1743. PMID: 20213100. PMCID: PMC11828204. https://doi.org/10.1007/s00432-010-0832-9
31. Wang FY, Kang CS, Wang-Gou SY, Huang CH, Feng CY, Li XJ. EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma. Cancer Lett. 2017;384:9-18. PMID: 27725228. https://doi.org/10.1016/j.canlet.2016.10.009
Review
For citations:
Sasmana I., Wiranata S., Kusuma I., Supadmanaba I., Wihandani D.M. Clinicopathological and Prognostic Significance of Epidermal Growth Factor-Like Domain 7 (EGFL7) Overexpression in Primary Central Nervous System Tumor: A Meta-Analysis. Innovative Medicine of Kuban. 2025;10(3):37-44. https://doi.org/10.35401/2541-9897-2025-10-3-37-44
Views:
25
Email this article 
